Driven from the convergence of Advanced Cell Engineering with Transformational Procedural Innovations

Breaking Through

Our three Innovation Pillars are Designed to Overcome the Major Barriers to Enable Cost-Effective Cell Therapies for Solid Tumors

Technology

Enhanced Potency → Engineered antigen presenting cells designed to overcome difficult to treat cancer

Broad spectrum targeting to address solid tumor heterogeneity and complexities. Design to overcome immune escape mechanisms.

Scalable Manufacturing → Derived from qualified allogenic hematopoietic stem cells

One universal product → all solid tumorsBreaks through manufacturing and logistic complexities of autologous cell therapies

Rapid Access → available when patient and providers need it

Point of care enabled precision medicine. Converts universal product with small patient tumor biopsy in real time with a simple disposable system. Making therapy available without delays, starting recovery earlier/faster

EXPANDING THE REACH OF CELL THERAPY WITHOUT LIMITS

The market opportunity is enormous

Tidewave bio’s product are agnostic to cancer type and could address a much larger segment of the entire solid tumor market

of all cancer and solid tumors are not adequately addressed

B+

Current market for CAR-T focused on small segment of hematological cancer (blood) which represent only 10% of all cancer

10-

100

market right now (Tidewave opportunity is 10x that)

Our goal

We are reimagining medicine for the future

Our Team

François Binette PhDCEO/Founder

François is a veteran executive with 30 years of experience in advanced cell and gene herapy product development across multiple therapeutic areas. His background includes leadership roles in both startups and major healthcare organizations. He previously served as President of Renovaro Biosciences, CEO of Rediens, and Global Head of Product Development at Lineage Cell Therapeutics, with prior experience at Johnson & Johnson, Medtronic, and Genzyme.

Smiling older man with white hair and glasses, wearing a blue shirt and black blazer against a plain gray background.

Michael Montgomery, MDCMO/ Co-founder

Michael is a physician-scientist with over 25 years of experience in internal medicine, developmental biology, and drug development. He has held senior leadership roles in both biotech startups and major pharma, including Centocor, Johnson & Johnson, and Incyte. He co-founded the Proof-of-Concept Team at J&J and led Global Medical Affairs at Incyte.

Vertical gradient background transitioning from dark teal at the top to lighter teal at the bottom.

“Confidential” PHDHead Translational Science

Stealth

Katherine Mercier Fractional COO

Katherine is a biopharmaceutical executive with over 20 years of global experience in Technical Operations, CMC and Quality Assurance across biologics, cell therapies and combination products. She has led teams through clinical and commercial manufacturing, regulatory inspections, and product launches. Before joining Tidewave Bio, Katherine served as Vice President of Technical Operations at Evofem Biosciences and held leadership roles at Vital Therapies, Dendreon, and Sandoz. She is passionate about advancing innovative therapies through robust CMC and GMP strategies that enable seamless scale-up and successful commercialization.

Woman with long brown hair wearing a black jacket and a striped scarf, smiling slightly.

Erika von Euw PhDScientific Advisor

Erika von Euw, PhD is a Life sciences executive with >20 years of experience in translational oncology/drug development. She has expertise in a wide range of
therapeutic modalities, with a strong focus on cell therapy and immuno-oncology. Erika has led the development of innovative immune-oncology platforms from discovery to IND. She holds a PhD in immunology and Oncology and has authored 30+ peer-reviewed publications.

Smiling middle-aged man with dark hair wearing a black jacket against a white background.

David WhelanStrategic Advisor

Dave Whelan has devoted his career to building businesses and inspiring trepreneurs at the intersection of Technology, health, and wellness. Dave works with organizations and entrepreneurs across the country and around the world, through his consultancy Bespoke Strategy, as well as collaborations with Wavemaker Three-Sixty Health and Big4Bio. He has held senior roles with BioscienceLA and New York Genome Center, among others. He hold an MBA from UCLA Anderson School and a BS Symbolic Systems from Stanford University.

Smiling male doctor wearing a white coat and red tie against a blue background.

Saeed Sadeghi MDClinical advisor

Dr. Saeed Sadeghi is a hematologist and medical oncologist in Santa Monica, specializing in breast, gynecological, and hepatobiliary cancers. Board-certified in internal medicine, hematology, and oncology, he participates in UCLA Health clinical trials and has led research on breast and epatobiliary cancers. Dr. Sadeghi received his medical degree from the St. Louis University School of Medicine. He then completed his internal medicine residency at the Los ngeles County+USC Medical Center, followed by his hematology-oncology fellowship at UCLA.